CagriSema: The Combination-Therapy Evidence Review

CagriSema combines semaglutide with cagrilintide for a dual-mechanism weight-loss therapy. Here's what REDEFINE 1 shows and how it compares to tirzepatide.

CagriSema is Novo Nordisk's fixed-dose combination of semaglutide and cagrilintide — a dual-action therapy combining GLP-1 receptor agonism with amylin receptor agonism. The pharmacologic rationale is that amylin and GLP-1 pathways work on complementary satiety mechanisms, potentially producing greater weight loss than semaglutide alone. The REDEFINE trial program is the phase 3 registration effort testing that hypothesis.

The data to date: CagriSema produces meaningful weight loss above semaglutide alone, though the effect size has been somewhat less dramatic than some pre-trial projections suggested. It appears to be a genuine advance over semaglutide monotherapy but not a knockout blow against tirzepatide's efficacy leadership.

The Pharmacologic Rationale

Amylin is a pancreatic hormone co-secreted with insulin that contributes to post-meal satiety and glucose control. Amylin analogs like cagrilintide activate calcitonin and amylin receptors in the central nervous system to reduce food intake through mechanisms distinct from GLP-1. Combining amylin agonism with GLP-1 agonism targets two overlapping but non-identical satiety pathways, with the hope of producing additive or synergistic weight-loss effects.

This is conceptually similar to tirzepatide's dual GLP-1/GIP agonism, though the specific targets and mechanisms are different. The broader industry thesis is that multi-receptor targeting can produce larger weight-loss effects than single-receptor drugs.

REDEFINE 1 Results

REDEFINE 1, the pivotal obesity phase 3 trial, showed CagriSema producing approximately 22.7% mean body weight reduction at 68 weeks. Compared to semaglutide alone at ~16.1%, CagriSema offers roughly 6-7 percentage points of additional weight loss. Compared to cagrilintide alone at ~11.5%, the combination offers more than 10 percentage points of additional loss. The combination appears additive in direction but with somewhat less than fully additive magnitude.

How This Compares to Tirzepatide

Tirzepatide at 15 mg produces approximately 20-21% mean weight loss in SURMOUNT-1, with SURMOUNT-5 showing a head-to-head advantage over semaglutide 2.4 mg of about 6-7 percentage points. CagriSema's performance is in roughly the same magnitude range as tirzepatide, suggesting the two drugs are approximately comparable in top-line efficacy. A direct head-to-head trial would be needed for a definitive comparison, and Novo has indicated plans for such a trial.

Tolerability

CagriSema's tolerability profile is similar to the GLP-1 class in general — gastrointestinal adverse events most common, generally manageable with dose titration. The amylin component adds some specific tolerability considerations, including more frequent nausea at initiation, but does not appear to introduce qualitatively new safety concerns. Injection-site reactions are comparable to semaglutide alone.

Why the Pre-Trial Expectations Were Higher

Some early commentary on CagriSema suggested it might exceed 25% mean weight loss based on phase 2 data. The phase 3 result at ~22.7% is below those expectations, though still clinically meaningful. The discrepancy reflects the general pattern in which phase 3 trials in broader populations often show somewhat smaller effects than phase 2 trials in more selected populations — not a specific CagriSema failure, but a regression-to-the-mean effect common in drug development.

Commercial and Clinical Positioning

If approved, CagriSema will enter the market as Novo Nordisk's highest-efficacy weight-management option, likely positioned as a premium product above the existing Wegovy franchise. Commercial pricing and access policies will shape uptake. Novo's commercial strategy appears oriented toward positioning CagriSema for patients whose weight-loss response to semaglutide alone is inadequate.

Broader Pipeline Context

CagriSema is one of several multi-receptor candidates advancing through development. Retatrutide (triple agonist, Eli Lilly), various GLP-1/glucagon dual agonists, and other combinations are in earlier stages. If CagriSema reaches market first among the post-tirzepatide combinations, it will define the premium segment until retatrutide and other candidates arrive. See our related reviews on retatrutide phase 2 and SURMOUNT-5 fact check.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.